pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-10a |
Genomic Coordinates | chr17: 48579838 - 48579947 |
Synonyms | MIRN10A, hsa-mir-10a, miRNA10A, mir-10a, MIR10A |
Description | Homo sapiens miR-10a stem-loop |
Comment | This human miRNA was predicted by computational methods using conservation with mouse and Fugu rubripes sequences . |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-10a-3p | ||||||||||||||||||||||||
Sequence | 63| CAAAUUCGUAUCUAGGGGAAUA |84 | ||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | GCFC2 | ||||||||||||||||||||
Synonyms | C2orf3, DNABF, GCF, TCF9 | ||||||||||||||||||||
Description | GC-rich sequence DNA-binding factor 2 | ||||||||||||||||||||
Transcript | NM_003203 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on GCFC2 | |||||||||||||||||||||
3'UTR of GCFC2 (miRNA target sites are highlighted) |
>GCFC2|NM_003203|3'UTR 1 ATAAACTTTATTGGAAAATGCTAAAATTTTAATATAGTTACACTCAGTTCCTTTGTTTGAGAAGAAGCTGGTGCCTCTCT 81 CTTCTTTATTCCCTGTAATAGAAGGTAGGATTTGAAAAAAAGCAGGACTCCACCTCTGTATTCCCCCGTGCTTTACCTTC 161 TGGCATCATGAAAAGCTGCCATGATTCTGTGGTGTTCTAAGGAATTAAATGCACTGGAGCTTTAAGAGCTCAACGTGTTT 241 CCCTTTGATTCTTTTGGCTGGTCTTTCAATTTTCTTAAGAGGGGAACTGGAGAAACCTTGCTAAAGGTTTTAGCTTAAGT 321 GAGCATGCTACTAAGTCTTCTGTCCTGAACCACAATAATATCTTTTAGTTCTCTTTAACTACCTTTATTTAAAAATAAGT 401 CAATATGAAAATCTCAGTTGGAGTGAATTATTTGCTAAGTATTAAATGATTAAGGCATGTGCCGATTGTCAAATTATCCT 481 TCAGAAATCTGTACCAATTTAATGTACCAACATAAGCATAAGTGAGTGCCAATGAATCCCTACCAGCAGTAGTTATTATC 561 CTTTTTAAAAATGCATTGAAAATTTGAAAGGTAAAAATCTTATTTTAATAGCGTATTTTGTGTTGGCTATTAGAGAGTAA 641 ACATATTGGTTTTGGCCATTTGTAATTATTTCTGAAATATCCATCTTTTTCTTATGGACTTTAAGACCTTTATATTTTTA 721 AAGATATTGATTTTTTGCCCATGCTTGTGGCAGAAGTTTTCCTTATTTGCCATTTTTCTTTTATTTTTTTTTTAATTGTA 801 TTTTTTGAGACAGGGTCTGGCTCTGTCACCCAGGCTGGAGAGTAGTGGCACAATCTCGGCTCACTGCAACCTCTGCCTTC 881 TGGGCTCAAGCAATCCTCCCACTTCAACCTCCCAAGTAGCTGGGACTATAGGCATGCGCCACCATGCCCAGCTGATTTTT 961 GTAATTTTTTGTAGAGATGGGGTTTCGTGACATTGCCCAGGCTGGTCTCGAACTCTTGAGCTCAAGCAGTCTACCCACCT 1041 TGACCTCCCAAAGTGCTGGGATTACAGGCTTGAGCAACCATGTTTGGCCTTTCTTTTAAATTTGTTGATGTTTTTTGAAG 1121 CATTAAGTCATTACTTATTAGCAAGTTACTATTTTGTTTTTTTGTCATTGGTGGTAGGACTAAGAAGGAAACAGATATTT 1201 TAAATACTCACAACATGTGATTCATTTTCTGATAAAATATTTGTCTAATAAAACAGAGGCAAGATAATTTAATCAAAAGA 1281 AATTAAGAAAATTTTCCAAAAATGTTAGTTTACTAGTAATTTTTCTAAGTCTACTTATTAAATAACTTAAGGGAAACTGT 1361 AAATATATTTTGCAAATTGTTGTTCAAAAGATAATTGGAAAAAATTGAATATATTGTAGGATTTGAATATACAGCCTACT 1441 TTTATGTCACCTCTACCTTCAAAACTACATATAATTTATTTTAGGAGTTGGATTTGTTATGTCTGTTGCAGTGAGGACTT 1521 GTGATTCACTGGTATGAAGAATTTTTTGATGTTTATATTAGTAACAAAATTATACAAGGATAGAATCTCATCTAGAAAAT 1601 GCAAACTATTGTTGAAAAGCAGTTAGCATTTCCACACAACCGCTGTCCCCAGAGATAACTGCTGTTTTCATTTTAATGTT 1681 ATCCTTTTAGACCTTTTCTCTATTTACAAAAATGTTACGTGTTTCTATGTGTACATAGTTTTGGGTTTTTTTTTTTTTTT 1761 TACGTAAGTGGCAGACACTTTATTGCACATGAAATTTGTAATTTTTTTCTATTTAAGTACACATTTGGAAATTATCCTCT 1841 GACTTTTGGATTTTTAACTAAATATGTTGGACGTGTTCCTTTATATATTTAAGTTCAGCACAGAAACTTTCCTACCTTTT 1921 TGTGGAAGATAAAATATTAAAACTGCTTTCAAAACTACAAAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | Flp-In T-REx 293-hAGO1 cells | ||||||
Location of target site | CDS | ||||||
Original Description (Extracted from the article) |
...
Validation of interactions identified by CLASH suppports their reliability.
... - Helwak A; Kudla G; Dudnakova T; Tollervey D, 2013, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Helwak A; Kudla G; Dudnakova T; Tollervey D - Cell, 2013
MicroRNAs (miRNAs) play key roles in gene regulation, but reliable bioinformatic or experimental identification of their targets remains difficult. To provide an unbiased view of human miRNA targets, we developed a technique for ligation and sequencing of miRNA-target RNA duplexes associated with human AGO1. Here, we report data sets of more than 18,000 high-confidence miRNA-mRNA interactions. The binding of most miRNAs includes the 5' seed region, but around 60% of seed interactions are noncanonical, containing bulged or mismatched nucleotides. Moreover, seed interactions are generally accompanied by specific, nonseed base pairing. 18% of miRNA-mRNA interactions involve the miRNA 3' end, with little evidence for 5' contacts, and some of these were functionally validated. Analyses of miRNA:mRNA base pairing showed that miRNA species systematically differ in their target RNA interactions, and strongly overrepresented motifs were found in the interaction sites of several miRNAs. We speculate that these affect the response of RISC to miRNA-target binding.
LinkOut: [PMID: 23622248]
|
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
62 hsa-miR-10a-3p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT038671 | VPS13D | vacuolar protein sorting 13 homolog D | ![]() |
1 | 1 | |||||||
MIRT038672 | GTF2I | general transcription factor IIi | ![]() |
1 | 1 | |||||||
MIRT038673 | ACLY | ATP citrate lyase | ![]() |
1 | 1 | |||||||
MIRT038674 | CLIC4 | chloride intracellular channel 4 | ![]() |
1 | 1 | |||||||
MIRT038675 | NCBP2 | nuclear cap binding protein subunit 2 | ![]() |
1 | 1 | |||||||
MIRT038676 | GCFC2 | GC-rich sequence DNA-binding factor 2 | ![]() |
1 | 1 | |||||||
MIRT056055 | COMMD3 | COMM domain containing 3 | ![]() |
![]() |
2 | 6 | ||||||
MIRT080401 | ONECUT2 | one cut homeobox 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT089339 | PCBP1 | poly(rC) binding protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT217793 | HBS1L | HBS1 like translational GTPase | ![]() |
![]() |
2 | 2 | ||||||
MIRT281381 | MAPK6 | mitogen-activated protein kinase 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT303046 | B3GNT2 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT446082 | RCOR3 | REST corepressor 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446109 | TSC22D2 | TSC22 domain family member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT448460 | SMC3 | structural maintenance of chromosomes 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449067 | ZNF24 | zinc finger protein 24 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449685 | CDR1 | cerebellar degeneration related protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT450363 | GRAMD3 | GRAM domain containing 2B | ![]() |
![]() |
2 | 2 | ||||||
MIRT463590 | ZBTB38 | zinc finger and BTB domain containing 38 | ![]() |
![]() |
2 | 2 | ||||||
MIRT466662 | TAF1D | TATA-box binding protein associated factor, RNA polymerase I subunit D | ![]() |
![]() |
2 | 6 | ||||||
MIRT467571 | SLITRK4 | SLIT and NTRK like family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT468557 | SERINC3 | serine incorporator 3 | ![]() |
![]() |
2 | 10 | ||||||
MIRT469840 | R3HDM4 | R3H domain containing 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT476235 | GNPNAT1 | glucosamine-phosphate N-acetyltransferase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT480076 | CALU | calumenin | ![]() |
![]() |
2 | 4 | ||||||
MIRT480825 | BLCAP | bladder cancer associated protein | ![]() |
![]() |
2 | 10 | ||||||
MIRT485713 | CASP16 | caspase 16, pseudogene | ![]() |
![]() |
2 | 8 | ||||||
MIRT500591 | UQCRFS1 | ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT507451 | EIF6 | eukaryotic translation initiation factor 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT507470 | EDEM3 | ER degradation enhancing alpha-mannosidase like protein 3 | ![]() |
![]() |
2 | 6 | ||||||
MIRT508618 | HOXC4 | homeobox C4 | ![]() |
![]() |
2 | 8 | ||||||
MIRT525776 | SOD2 | superoxide dismutase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT529014 | GYPA | glycophorin A (MNS blood group) | ![]() |
![]() |
2 | 2 | ||||||
MIRT536731 | IGF1 | insulin like growth factor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT537307 | FRS2 | fibroblast growth factor receptor substrate 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT548439 | ELMOD2 | ELMO domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT550928 | ATG2B | autophagy related 2B | ![]() |
![]() |
2 | 2 | ||||||
MIRT552415 | ZNF460 | zinc finger protein 460 | ![]() |
![]() |
2 | 4 | ||||||
MIRT553138 | UBE2H | ubiquitin conjugating enzyme E2 H | ![]() |
![]() |
2 | 2 | ||||||
MIRT554946 | RAP1A | RAP1A, member of RAS oncogene family | ![]() |
![]() |
2 | 2 | ||||||
MIRT556315 | MAP2K4 | mitogen-activated protein kinase kinase 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT557057 | HOXB3 | homeobox B3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT557743 | FUT4 | fucosyltransferase 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT558489 | DBN1 | drebrin 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT559638 | AKAP10 | A-kinase anchoring protein 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT568118 | CDC27 | cell division cycle 27 | ![]() |
![]() |
2 | 2 | ||||||
MIRT574413 | TFAP2A | transcription factor AP-2 alpha | ![]() |
![]() |
2 | 2 | ||||||
MIRT611420 | ZNF431 | zinc finger protein 431 | ![]() |
![]() |
2 | 4 | ||||||
MIRT616545 | NFATC2 | nuclear factor of activated T-cells 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT628408 | C1orf21 | chromosome 1 open reading frame 21 | ![]() |
![]() |
2 | 2 | ||||||
MIRT629513 | QRSL1 | glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT635884 | SIX3 | SIX homeobox 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT643154 | GOLIM4 | golgi integral membrane protein 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT645603 | MRPS15 | mitochondrial ribosomal protein S15 | ![]() |
![]() |
2 | 2 | ||||||
MIRT654270 | RGS17 | regulator of G protein signaling 17 | ![]() |
![]() |
2 | 2 | ||||||
MIRT658811 | EFNA5 | ephrin A5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT659613 | CELSR2 | cadherin EGF LAG seven-pass G-type receptor 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT697603 | YAP1 | Yes associated protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT700703 | PODXL | podocalyxin like | ![]() |
![]() |
2 | 2 | ||||||
MIRT705319 | ATP6V1G1 | ATPase H+ transporting V1 subunit G1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT721291 | TRABD2A | TraB domain containing 2A | ![]() |
![]() |
2 | 2 | ||||||
MIRT734812 | EPHA8 | EPH receptor A8 | ![]() |
1 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|